FV-082: A safer orally active broad-spectrum antiepileptic drug candidate

Broad-spectrum antiepileptic drugs (AEDs) are valued for their potential to treat refractory epilepsy and, as general ‘neurostabilizers’, have been employed for a variety of neurological diseases including migraine, bipolar disorder, and neuropathic pain. However, the benefits of historical AEDs have been constrained by unintended CNS side effects. Combining proprietary breakthrough chemistry with Fluorinov Pharma and NIH's in vivo phenotypic screening strategy identified three completely novel candidate drugs, including FV-082, with superior safety and efficacy profiles.